Approved for use in adult patients with metastatic RET fusion-positive NSCLC, adult and paediatric patients ≥ 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy and adult and paediatric patients ≥ 12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Product Introduction :
Selpercatinib is a highly selective receptor tyrosine kinase RET (rearranged during transfection) inhibitor developed by Loxo Oncology for the treatment of various solid tumours including non-small cell lung cancer (NSCLC) and thyroid cancer. Abnormally activated RET can act as an oncogene in various cancers; RET fusions retaining the kinase domain are drivers of NSCLC and papillary thyroid cancer, and activating RET mutations are associated with different phenotypes of multiple endocrine neoplasia type 2 and sporadic medullary thyroid cancer (MTC). Selpercatinib was approved in the US in May 2020.
Administration and Dosage :
The recommended dose of the drug is 120 mg (in patients weighing < 50 kg) or 160 mg (in patients weighing ≥ 50 kg) orally twice daily (≈ 12 h) until disease progression or the emergence of unacceptable toxicity.